Health Canada Approves CAMBIA® for the Treatment of Acute Migraine – Market Wire

CAMBIA ® is expected to be launched in Canada in the second half of 2012. CAMBIA ®, a novel, water-soluble, buffered diclofenac potassium powder engineered using Dynamic Buffering Technology™, a patented absorption-enhancing technology developed by a …

Leave a Reply

Your email address will not be published.